Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

One of the classes of medications ­­– glucagon-like peptide-1 receptor agonists (GLP-1) – treats Type 2 diabetes by ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...